Results 41 to 50 of about 598,726 (234)

Monkeypox virus-infected individuals mount comparable humoral immune responses as Smallpox-vaccinated individuals

Nature Communications, 2023
In early 2022, a cluster of monkeypox virus (MPXV) infection (mpox) cases were identified within the UK with no prior travel history to MPXV-endemic regions.
Ashley D. Otter, Scott Jones, Bethany Hicks, Daniel Bailey, Helen Callaby, Catherine Houlihan, Tommy Rampling, Nicola Claire Gordon, Hannah Selman, Panayampalli S. Satheshkumar, Michael Townsend, Ravi Mehta, Marcus Pond, Rachael Jones, Deborah Wright, Clarissa Oeser, Simon Tonge, Ezra Linley, Georgia Hemingway, Tom Coleman, Sebastian Millward, Aaron Lloyd, Inger Damon, Tim Brooks, Richard Vipond, Cathy Rowe, Bassam Hallis   +26 more
doaj   +1 more source

Safety and immunogenicity of IMVAMUNE®, a third-generation vaccine based on the modified vaccinia Ankara (MVA) strain

Биопрепараты: Профилактика, диагностика, лечение, 2023
In 1980, the World Health Assembly officially declared smallpox eradicated in the world, which allowed developed countries to stop preventive vaccination against this disease.
L. F. Stovba, O. V. Chukhralya, N. K. Chernikova, A. L. Khmelev, S. V. Borisevich   +4 more
doaj   +1 more source

The Global Monkeypox (Mpox) Outbreak: A Comprehensive Review

Vaccines, 2023
Monkeypox (Mpox) is a contagious illness that is caused by the monkeypox virus, which is part of the same family of viruses as variola, vaccinia, and cowpox.
Shriyansh Srivastava, Sachin Kumar, Shagun Jain, Aroop Mohanty, Neeraj Thapa, Prabhat Poudel, Krishna Bhusal, Zahraa Haleem Al-qaim, Joshuan J. Barboza, Bijaya Kumar Padhi, Ranjit Sah   +10 more
doaj   +1 more source

Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial

PLoS ONE, 2018
Background Modified Vaccinia Ankara (MVA) is a live, viral vaccine under advanced development as a non-replicating smallpox vaccine. A randomised, double-blind, placebo-controlled phase III clinical trial was conducted to demonstrate the humoral ...
E. Overton, S. Lawrence, E. Wagner, Katrin Nopora, Siegfried Rösch, P. Young, D. Schmidt, Christian Kreusel, Sonja De Carli, T. Meyer, H. Weidenthaler, N. Samy, P. Chaplin   +12 more
semanticscholar   +1 more source

Vaccinia virus-based vector against infectious diseases and tumors

Human Vaccines & Immunotherapeutics, 2021
Vaccinia virus was used to prevent smallpox. After the World Health Organization declared smallpox extinct, vaccinia virus has been explored for the development of vaccines against a variety of infectious diseases.
Ziling Zhang, Lanlan Dong, Chen Zhao, Peiyong Zheng, Xiaoyan Zhang, Jianqing Xu   +5 more
doaj   +1 more source

Use of Vaccinia Virus Smallpox Vaccine in Laboratory and Health Care Personnel at Risk for Occupational Exposure to Orthopoxviruses - Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2015.

MMWR. Morbidity and mortality weekly report, 2016
On June 25, 2015, the Advisory Committee on Immunization Practices (ACIP) recommended routine vaccination with live smallpox (vaccinia) vaccine (ACAM2000) for laboratory personnel who directly handle 1) cultures or 2) animals contaminated or infected ...
B. Petersen, T. Harms, M. Reynolds, L. Harrison   +3 more
semanticscholar   +1 more source

Remaining Questions about Clinical Variola Major

Emerging Infectious Diseases, 2011
After the recent summary of World Health Organization–authorized research on smallpox, several clinical issues remain. This policy review addresses whether early hemorrhagic smallpox is disseminated intravascular coagulation and speculates about the ...
J. Michael Lane
doaj   +1 more source

Populations Addressed in Vaccines Approved via the European Medicines Agency

Clinical Pharmacology &Therapeutics, EarlyView.
Therapeutic and prophylactic agents require robust evidence before patient use. Randomized controlled trials are essential for evaluating safety and efficacy but often exclude specific populations that are also targets for the intervention. This study assessed which populations are included in vaccine registration studies and/or addressed in label ...
Débora D. Gräf, Lukas Westphal, Jonathan Kimmelman, Christine E. Hallgreen   +3 more
wiley   +1 more source

Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox.

New England Journal of Medicine, 2019
BACKGROUND Many countries have stockpiled vaccines because of concerns about the reemergence of smallpox. Traditional smallpox vaccines are based on replicating vaccinia viruses; these vaccines have considerable side effects.
P. Pittman, M. Hahn, Heechoon Lee, Craig D Koca, N. Samy, D. Schmidt, Joachim Hornung, H. Weidenthaler, C. Heery, T. Meyer, G. Silbernagl, J. Maclennan, P. Chaplin   +12 more
semanticscholar   +1 more source

Monkeypox in humans – the review

Journal of Education, Health and Sport, 2022
Monkeypox is an emerging zoonotic disease caused by the monkeypox virus with a presentation similar to smallpox. Being previously endemic to Africa, now the disease is spreading across the world, causing fear of a potential next pandemic.
Konrad Warchoł, Adam Jasiura , Kamila Giżewska, Aleksandra Wójcik , Sylwiusz Niedobylski   +4 more
doaj   +1 more source